Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Apr 1;109(4):djw315.
doi: 10.1093/jnci/djw315.

Burdensome Research Procedures in Trials: Why Less Is More

Affiliations

Burdensome Research Procedures in Trials: Why Less Is More

Jonathan Kimmelman et al. J Natl Cancer Inst. .

Abstract

A large volume of trials involve invasive, nontherapeutic research procedures, like organ biopsy or sham surgeries, that can pose risks comparable with the experimental treatment itself but that have no direct benefit for volunteers. Though such procedures can enhance the value of clinical investigations, recent studies suggest that many studies involving invasive, nontherapeutic research procedures are not well planned and reported; some studies suggest that their results are often not utilized in the planning of new investigations. This commentary offers recommendations for how investigators, sponsors, and ethics committees might improve evaluation and implementation of studies involving invasive nontherapeutic procedures. We conclude by urging more demanding scientific standards for the rationale, design, and reporting of burdensome, nontherapeutic research procedures-particularly where they involve risk of serious complications.

PubMed Disclaimer

Comment in

Similar articles

Cited by

References

    1. Goulart BH, Clark JW, Pien HH, et al. Trends in the use and role of biomarkers in phase I oncology trials. Clin Cancer Res. 2007;13(22 Pt 1):6719–6726. - PubMed
    1. Wong HH, Barton C, Acton G, et al. Trends in the characteristics, dose-limiting toxicities and efficacy of phase I oncology trials: The Cancer Research UK experience. Eur J Cancer. 2016;66:9–16. - PubMed
    1. Sweis RF, Drazer MW, Ratain MJ.. Analysis of impact of post-treatment biopsies in phase I clinical trials. J Clin Oncol. 2016;344:369–374. - PMC - PubMed
    1. U.S. Food and Drug Administration. Hematology/oncology (cancer) approvals and safety notifications. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174.htm. Accessed June 17, 2016.
    1. Yap TA, Sandhu SK, Workman P, et al. Envisioning the future of early anticancer drug development. Nat Rev Cancer. 2010;107:514–523. - PubMed

MeSH terms